Over the past year, Amy Krambeck, MD, chief of the Division of Endourology and Stone Disease and professor of Urology at Northwestern Medicine and a world leader in Holmium Laser Enucleation of the Prostate (HoLEP), has diagnosed prostate cancer in nearly 13% of her patients who underwent HoLEP for benign prostatic hyperplasia. She has partnered with Ashley Ross, MD, PhD, associate professor of Urology at Northwestern Medicine and a nationally recognized expert in prostate cancer, to develop an active surveillance protocol for the management of incidental prostate cancer after HoLEP. They explain their recommendations in the latest episode of the Better Edge podcast.
